Angitia Biopharmaceuticals Completes US$40M Second Close of Series B Extension Financing
Angitia Biopharmaceuticals, a global clinical-stage biotechnology company announces the completion of an additional US$40M Series B Extension financing in January 2024 led by YueKai Health, a market-oriented VC funded by GZHT Technology Holding and managed by Yuekai Capital. Combined with the US$46M Series B Extension financing completed in October 2023, Angitia has now raised US$86M in the Series B Extension.
Angitia Biopharmaceuticals Announces the First Subject Dosed in a Phase III Registrational Trial of AGA111, a Drug Candidate for Enhancing Spinal Fusion
Guangzhou, China and Woodland Hills, California, USA – December 8th, 2023, Angitia Biopharmaceuticals, a global clinical-stage biotechnology company, announced today that the first subject has been successfully dosed in a Phase III registrational clinical trial of AGA111.
Angitia Biopharmaceuticals Announces Completion of $46M Series B Extension Financing
October 19, 2023 - Angitia Biopharmaceuticals, a global clinical-stage biotechnology company focused on the discovery and development of breakthrough therapies that address the unmet medical needs of patients with serious musculoskeletal disease, announced the closing of a US$46M Series B extension financing led by Morningside Group, and syndicated by 3H Health Investment, OrbiMed, Yonghua Capital, Legend Capital, Oriza Holdings and Elikon Venture. The Series B extension financing brings the total size of the funding round to US$170M. Proceeds from the financing will be used to accelerate the global development of Angitia’s innovative drug candidates for musculoskeletal diseases including AGA111, AGA2115 and AGA2118.